ARTICLE | Company News
India approves Epirus' Remicade biosimilar
September 16, 2014 1:50 AM UTC
The Drug Controller General of India (DCGI) approved manufacturing and marketing of autoimmune therapy Infimab infliximab from Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS).
Infimab, formerly BOW015, is India's first approved biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK). The approval is Epirus' first anywhere. ...